Xaliproden
Xaliproden is a drug that was under development for the treatment of Amyotrophic lateral sclerosis (ALS) and chemotherapy-induced peripheral neuropathy. It was developed by Sanofi-Aventis, but its development was discontinued in 2006 due to unfavorable results in phase III clinical trials.
History[edit]
Sanofi-Aventis, a global pharmaceutical company, began the development of Xaliproden in the early 2000s. The drug was intended to treat Amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, and chemotherapy-induced peripheral neuropathy, a common side effect of cancer treatment.
Mechanism of Action[edit]
Xaliproden is a serotonin 1A receptor agonist. The serotonin 1A receptor is a subtype of the serotonin receptor, which is a group of G protein-coupled receptors and ligand-gated ion channels found in the central and peripheral nervous systems. By acting on this receptor, Xaliproden was believed to have neuroprotective effects.
Clinical Trials[edit]
Xaliproden underwent phase III clinical trials for the treatment of ALS and chemotherapy-induced peripheral neuropathy. However, the results were not favorable, and Sanofi-Aventis discontinued the development of the drug in 2006.
Discontinuation[edit]
The discontinuation of Xaliproden's development was a significant setback for Sanofi-Aventis. The company had invested heavily in the drug's development, and the failure of the phase III trials represented a significant financial loss.
See Also[edit]
- Amyotrophic lateral sclerosis
- Chemotherapy-induced peripheral neuropathy
- Sanofi-Aventis
- Serotonin 1A receptor
